File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Liver - Autoimmune Conditions - Primary Biliary Cirrhosis Investigations Written by Dr Sebastian Zeki

Recognises and appropriately investigates patients with auto-immune
liver diseases

Aware of management and complications of autoimmune liver
disease including extra-hepatic manifestations and associations
including malignant complications in PSC

Appreciates and understands that this range of liver disease is
frequently under-diagnosed and may have been inappropriately

Selects appropriate immunomodulatory therapy has awareness of
side effects and may well require specialist care

Responds urgently to the management challenge of these severe and
often acute diseases and involves more specialist services where

Primary Biliary Cirrhosis Investigations

Primary Biliary Cirrhosis Investigations Complications:Metabolic bone disease (osteoporosis plus malacia).Hypercholesterolaemia and xanthomas.Malabsorption ( due to decreased bile salt secretion.Anaemia. The target autoantigens (=the M2 antigens)the E2 subunits of the pyruvate dehydrogenase complex, the branched chain 2-oxo-acid dehydrogenase complex,the ketoglutaric acid dehydrogenase complexAll take part in oxidative phosphorylationVery homologousAntibody titers do not correlate with disease severity or rate of progression Sensitivity of 95%, spec of 98%No apparent difference in the clinical spectrum or course of patients with PBC who are AMA-positive or AMA-negative CD8+ CD4+ Foamy degeneration of hepatocytes Toxins (eg bile acid) cause hepatocyte Laboratory testsEosinophils-can be elevated early in the disease course.Antimitochondrial antibodies are present in 95 %.AMA is 95 % sensitive and 98 % specific.13 % of first-degree relatives of PBC positive are AMA positive, suggesting they are susceptible to developing PBC.Antinuclear antibodies are present in 70%.A variety of ANA staining patterns is present.ANA positive is associated with overlap and also signify worse prognosis.PBC patients who are AMA negative and have a positive ANA, a disease called autoimmune cholangitis or AMA negative PBC, have the same outcomes as those who are AMA positive and ANA negative.Hyperlipidemia occurs in 50%.LDL and VLDL mildly elevated.HDL’s are usually very elevated.Patients are not at increased cardiovascular risk. Liver biopsy features: Mononuclear inflammatory infiltrate. Formation of lymphoid aggregates CD4+ and CD8+ cells are present in high concentration in the portal triads of patients with PBC, often surrounding and infiltrating necrotic bile ducts- they both target amino acids 159-167 of PDC-E2. Epithelioid granulomas. Bile duct damage. Foamy degeneration of hepatocytes. Always have high hepatic alk phos levelsThe value tends to reach a plateau early in the course of the disease and then usually fluctuates within 20 % of this value. The serum levels of aminotransferases is normal or slightly elevated, rarely increased > 5x normal.Fluctuate within a relatively narrow range,If rise to > 10x normal consider overlap syndrome The serum bilirubin concentration is usually normal early in the course of the disease but becomes elevated in most patients as the disease progresses.Both the direct and indirect fractions are increased.An elevated serum bilirubin is a poor prognostic sign. OtherIncreased IgM, ceruloplasmin, bile acids (which are strikingly elevated), and hyaluronate.Rising hyaluronate levels correlate with the serum bilirubin and histologic worsening of the disease. Genetically susceptible host with an inability to suppress T-cell attack on bile duct epithelial cells Age > 21 (?specific hormone profile) Triggering event (bile duct epithelial damage?, drug reaction?, gallstones?, viral infection? Progressive damage to bile duct epithelial cells Increased expression of HLA class I and II antigens Retention of toxic substances eg bile acids Cholestasis Gradual loss of bile ducts Progressive portal and periportal scarring Cirrhosis and portal hypertension Hepatic failure and complications of portal hypertension Written by Dr Sebastian Zeki

Related Stories

Priming and Maintenance of Adaptive Immunity in the Liver

In vitro Gluten Degradation Using Recombinant Eurygaster Integriceps Prolyl Endoprotease: Implications for Celiac Disease

Landau-Kleffner Syndrome, Attention-Deficit/Hyperactivity Disorder (ADHD), and Viral/Autoimmune Encephalitis: Challenges in the Diagnosis and Management of a Six-Year-Old Boy

Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis

Chronic liver disease and management with silymarin: an introductory review of a clinical case collection